BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 28069005)

  • 21. Canine CD20 gene.
    Kano R; Inoiue C; Okano H; Yamazaki J; Takahashi T; Watari T; Tokuriki M; Hasegawa A
    Vet Immunol Immunopathol; 2005 Dec; 108(3-4):265-8. PubMed ID: 16061290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
    Klapper W; Stoecklein H; Zeynalova S; Ott G; Kosari F; Rosenwald A; Loeffler M; Trümper L; Pfreundschuh M; Siebert R;
    Leukemia; 2008 Dec; 22(12):2226-9. PubMed ID: 18754028
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Whole genome sequencing analysis of high confidence variants of B-cell lymphoma in Canis familiaris.
    Sparks A; Woods JP; Bienzle D; Wood GA; Coomber BL
    PLoS One; 2020; 15(8):e0238183. PubMed ID: 32857815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A canine cancer-gene microarray for CGH analysis of tumors.
    Thomas R; Fiegler H; Ostrander EA; Galibert F; Carter NP; Breen M
    Cytogenet Genome Res; 2003; 102(1-4):254-60. PubMed ID: 14970712
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
    Ok CY; Xu-Monette ZY; Tzankov A; O'Malley DP; Montes-Moreno S; Visco C; Møller MB; Dybkaer K; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Han van Krieken J; Ponzoni M; Farnen JP; Piris MA; Winter JN; Medeiros LJ; Young KH
    Cancer; 2014 Jun; 120(12):1818-29. PubMed ID: 24648050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of serum biomarkers for canine B-cell lymphoma by use of surface-enhanced laser desorption-ionization time-of-flight mass spectrometry.
    Gaines PJ; Powell TD; Walmsley SJ; Estredge KL; Wisnewski N; Stinchcomb DT; Withrow SJ; Lana SE
    Am J Vet Res; 2007 Apr; 68(4):405-10. PubMed ID: 17397297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic factors for treated canine malignant lymphoma.
    Kiupel M; Teske E; Bostock D
    Vet Pathol; 1999 Jul; 36(4):292-300. PubMed ID: 10421095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
    Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
    Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of Ki67 evaluated by flow cytometry in dogs with high-grade B-cell lymphoma.
    Poggi A; Miniscalco B; Morello E; Gattino F; Delaude A; Ferrero Poschetto L; Aresu L; Gelain ME; Martini V; Comazzi S; Riondato F
    Vet Comp Oncol; 2017 Jun; 15(2):431-440. PubMed ID: 26792094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclin D1-positive diffuse large B-cell lymphoma with IGH-CCND1 translocation and BCL6 rearrangement: a report of two cases.
    Al-Kawaaz M; Mathew S; Liu Y; Gomez ML; Chaviano F; Knowles DM; Orazi A; Tam W
    Am J Clin Pathol; 2015 Feb; 143(2):288-99. PubMed ID: 25596256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinicopathological features of double-hit B-cell lymphomas with MYC and BCL2, BCL6 or CCND1 rearrangements.
    Yoshida M; Ichikawa A; Miyoshi H; Kiyasu J; Kimura Y; Arakawa F; Niino D; Ohshima K
    Pathol Int; 2015 Oct; 65(10):519-27. PubMed ID: 26224092
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic significance of CD44v6 in diffuse large B-cell lymphoma.
    Inagaki H; Banno S; Wakita A; Ueda R; Eimoto T
    Mod Pathol; 1999 May; 12(5):546-52. PubMed ID: 10349995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive analysis of gene expression profiles reveals novel candidates of chemotherapy resistant factors in canine lymphoma.
    Suenaga M; Tomiyasu H; Watanabe M; Ogawa K; Motegi T; Goto-Koshino Y; Ohno K; Sugano S; Skorupski KA; Tsujimoto H
    Vet J; 2017 Oct; 228():18-21. PubMed ID: 29153103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of cyclin D1 mRNA overexpression in B-cell neoplasias by real-time reverse transcription-PCR of microdissected paraffin sections.
    Specht K; Kremer M; Müller U; Dirnhofer S; Rosemann M; Höfler H; Quintanilla-Martinez L; Fend F
    Clin Cancer Res; 2002 Sep; 8(9):2902-11. PubMed ID: 12231535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A morphological study of 608 cases of canine malignant lymphoma in France with a focus on comparative similarities between canine and human lymphoma morphology.
    Ponce F; Marchal T; Magnol JP; Turinelli V; Ledieu D; Bonnefont C; Pastor M; Delignette ML; Fournel-Fleury C
    Vet Pathol; 2010 May; 47(3):414-33. PubMed ID: 20472804
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of rituximab in the treatment of canine lymphoma: an ex vivo evaluation.
    Impellizeri JA; Howell K; McKeever KP; Crow SE
    Vet J; 2006 May; 171(3):556-8. PubMed ID: 16624725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
    Urban P; Vuaroqueaux V; Labuhn M; Delorenzi M; Wirapati P; Wight E; Senn HJ; Benz C; Eppenberger U; Eppenberger-Castori S
    J Clin Oncol; 2006 Sep; 24(26):4245-53. PubMed ID: 16963728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic and environmental risk indicators in canine non-Hodgkin's lymphomas: breed associations and geographic distribution of 608 cases diagnosed throughout France over 1 year.
    Pastor M; Chalvet-Monfray K; Marchal T; Keck G; Magnol JP; Fournel-Fleury C; Ponce F
    J Vet Intern Med; 2009; 23(2):301-10. PubMed ID: 19192140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of tyrosine-kinase receptor c-kit mutations, mRNA and protein expression in canine lymphoma: might c-kit represent a therapeutic target?
    Giantin M; Aresu L; Aricò A; Gelain ME; Riondato F; Comazzi S; Dacasto M
    Vet Immunol Immunopathol; 2013 Aug; 154(3-4):153-9. PubMed ID: 23791075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pax5 immunostaining in paraffin-embedded sections of canine non-Hodgkin lymphoma: a novel canine pan pre-B- and B-cell marker.
    Willmann M; Müllauer L; Guija de Arespacochaga A; Reifinger M; Mosberger I; Thalhammer JG
    Vet Immunol Immunopathol; 2009 Apr; 128(4):359-65. PubMed ID: 19100628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.